Kathryn A. Gold, MD

Kathryn A. Gold, MD, discusses the benefit of targeted therapies in patients with mutated lung cancers.

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Kathryn A. Gold, MD, associate professor of medicine, University of California, San Diego, discusses the future of osimertinib (Tagrisso) in the treatment of patients with EGFR-mutant lung cancer.

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, differentiates carcinogen-induced and virally associated head and neck squamous cell carcinoma.

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses approaching patients with HPV-positive head and neck cancer.

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses the current state of human papilloma virus (HPV)-related head and neck cancer.